Suraksha Diagnostic Limited

1. Diagnostic chain with in eastern India well positioned to leverage growth opportunity for organized diagnostic chains in the diagnostic services markets in eastern and north-eastern India.

2. Track record of profitability and financial performance.

3. Integrated diagnostics provider with one-stop solution offering pathology and radiology testing, and medical consultation services.

4. Technologically advanced clinical infrastructure and trained personnel providing diagnostic services.

5. Commitment to quality driving high individual consumer business share and customer retention.

6. Management team with relevant industry experience.

1. 95.48% of its Revenue from Operations in Fiscal 2024 was generated from West Bengal, and any loss of business in such region could have an adverse effect on its business, results of operations and financial condition.

2. The securities of certain of its Promoter Group members have been suspended from trading on a recognized stock exchange in the past. The company cannot assure you that there will be no such instances in the future which may adversely affect its operations, reputation and ability to raise capital through further public issue of securities.

3. The diagnostics industry in India is highly competitive and its inability to compete effectively from other healthcare service providers may adversely affect its business, results of operations and financial condition. Further, as of Financial Year 2024, the market share of the Company in its major market which is East India is 1.15-1.30%.

4. The B2B segment contributed to 6.17% of its Revenue from Operations in Fiscal 2024 and any non-renewal or cancellation of its arrangements with its institutional customers, including hospitals, and Public-Private Partnership (PPP) contracts may adversely affect its business, results of operations and financial condition.

5. Its Statutory Auditors have included certain emphasis of matters, and audit qualifications matters prescribed in the audit reports of the Company for Fiscals 2023 and 2024.

6. In the past, the company failed to comply with certain provisions of the Companies Act, 2013, and had to compound such non-compliances. The company cannot assure you that there will be no such non-compliances in the future and that the Company, Promoters, or Directors will not be subject to any penalty or additional payment.

7. Certain of its Promoters, Directors, Subsidiaries and Group Company are in businesses similar to its and have interests in certain companies, which are in similar businesses to its, and this may result in potential conflict of interest with the company.

8. Its Promoters and certain members of the company Promoter Group pledged some of the Equity Shares held by them in favour of Vistra ITCL (India) Limited, in its capacity as debenture trustee for the benefit of the debentureholders, as security for debentures issued by its Promoter Group entity, Tinni Investments Limited, and there are disposal restrictions created on Equity Shares held by certain other shareholders. Upon creation, any invocation of such pledge could dilute the aggregate shareholding of its Promoters, and such members of the company Promoter Group, which may cause a change in control of the Company and trigger an open offer requirement under the Takeover Regulations.

9. There are outstanding legal proceedings involving the Company, Subsidiaries, Promoters, Directors and Group Companies which may adversely affect its business, financial condition and results of operations.

10. The Company will not receive any proceeds from the Offer for Sale. The Selling Shareholders will receive the entire net proceeds from the Offer for Sale.